Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Denali Therapeutics Inc. (NASDAQ: DNLI).

Full DD Report for DNLI

You must become a subscriber to view this report.


Recent News from (NASDAQ: DNLI)

Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
Denali Therapeutics reports Q1 results
Denali Therapeutics (NASDAQ: DNLI ): Q1 EPS of -$0.26 More news on: Denali Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 11 2018 08:03
Denali Therapeutics Reports First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., May 11, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 201...
Source: GlobeNewswire
Date: May, 11 2018 08:00
Pushing Preclinical: Wave Of Early-Stage Biotech IPOs Tests Investor Risk Appetite
Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going publ...
Source: SeekingAlpha
Date: May, 09 2018 05:37
Oryzon Genomics on go with mid-stage study of Alzheimer's candidate ORY-2001
Madrid, Spain-based Oryzon Genomics announces that it has received regulatory sign-off for a Phase 2a clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: Alzheon, Denali Therapeutics, Inc., Wave Life Sciences, Healthcare stocks news...
Source: SeekingAlpha
Date: April, 04 2018 11:14
3 Things In Biotech, March 19: Progenics, Denali, Regeneron. Gains All Around
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Pro...
Source: SeekingAlpha
Date: March, 20 2018 08:00
Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights
SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has commenced dosing of its small molecule inhib...
Source: GlobeNewswire
Date: March, 19 2018 08:00
Premarket analyst action - healthcare
Cara Therapeutics (NASDAQ: CARA ) resumed with Buy rating and $22 (53% upside) price target at H.C. Wainwright. More news on: Cara Therapeutics Inc., Mirati Therapeutics, Inc., Fennec Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: March, 12 2018 08:38
Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine
Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de...
Source: SeekingAlpha
Date: February, 08 2018 15:26
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
Partnership aims to develop drugs for neurodegenerative diseases Denali will draw on Lonza’s expertise in developing and manufacturing complex biologic molecules  BASEL, Switzerland and SOUTH SAN FRANCISCO, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Lonza Pharma & Biot...
Source: GlobeNewswire
Date: February, 08 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1718.8618.9919.1218.6638194,762

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1744,75662,07072.1057Short
2018-08-1668,801100,57268.4097Short
2018-08-1530,16243,47869.3730Short
2018-08-1430,15050,99259.1269Short
2018-08-1365,136107,01160.8685Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DNLI.


About Denali Therapeutics Inc. (NASDAQ: DNLI)

Logo for Denali Therapeutics Inc. (NASDAQ: DNLI)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: DNLI)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 11 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 19 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 19 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 13 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: February, 13 2018

       

       


      Daily Technical Chart for (NASDAQ: DNLI)

      Daily Technical Chart for (NASDAQ: DNLI)


      Stay tuned for daily updates and more on (NASDAQ: DNLI)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: DNLI)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DNLI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of DNLI and does not buy, sell, or trade any shares of DNLI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/